- Home
- TALO vs MIRM Comparison
TALO vs MIRM Comparison
Compare TALO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | MIRM |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 5.7B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TALO | MIRM |
|---|---|---|
| Price | $13.32 | $123.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $18.00 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.7M | 785.1K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,780,070,000.00 | $19,138,000.00 |
| Revenue This Year | $4.18 | $26.22 |
| Revenue Next Year | N/A | $22.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.67 | $47.89 |
| 52 Week High | $17.05 | $119.49 |
Technical Indicators
Market Signals| Indicator | TALO | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 78.30 |
| Support Level | $10.49 | $87.93 |
| Resistance Level | $13.85 | N/A |
| Average True Range (ATR) | 0.53 | 4.98 |
| MACD | -0.10 | 2.49 |
| Stochastic Oscillator | 7.39 | 92.80 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.